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community-dwelling patients with diabetes aged between 20 and 85 in the 2006 and 
2007 Medical Expenditure Panel Survey (MEPS) consolidated data ﬁ les, a nationally 
representative survey linked to prescribed medicines ﬁ le. The main outcome measure 
was the total expenditures including inpatient and ambulatory care, excluding phar-
macy costs, in 2006 and 2007, respectively. The differences in the health-care costs 
between statin users and nousers were estimated from the interaction terms between 
time trend and statin use, using a generalized linear model with a log link and gamma 
distribution, controlling for the difference in the two groups and time trend. The other 
covariates included were socioeconomic variables, insurance status, and comorbid 
conditions. RESULTS: In 2006, the median total expenditures of the statin users and 
nonusers were $1787 (IQR $583–5993) and $1117 (IQR $215–5565), respectively. 
In the subsequent year, the median total expenditures of the statin users and nonusers 
were $1452 (IQR $443–6354) and $851 (IQR $180–4451), respectively. No statisti-
cally difference in the total expenditures between the two groups was found (param-
eter estimate 0.37, 95% CI −0.05, 0.79, P-value 0.086). CONCLUSIONS: No 
evidence supporting the reduction in health-care resource utilization following statin 
use was found. While our ﬁ nding shows that statin use did not lower subsequent 
health-care resource utilization, further research is needed to investigate the potential 
effect of the differences among the users and nonusers, and the potential effect of the 
differential slopes of the two groups on resource utilization overtime. 
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OBJECTIVES: To compare patients’ expenditure on utilization of high price new 
statin drugs. METHODS: This is a cross-sectional analysis. The hospital database of 
out-patients diagnosed as hyperlipidemia during 2003–2006 was retrieved for drug 
names and their costs. The expenditure for statin drugs per patient before and after 
a new statin was prescribed were compared. RESULTS: Before Fluvastatin 80 mg was 
included to the hospital formulary in 2003, the expenditure for statin drugs per patient 
was 8.27 USD. Average statins expenditure after 3 months of Fluvastatin 80 mg ﬁ rst 
prescribed was increased to be was 22.59 USD or 273%, with the market share only 
0.4% of all antihyperlipidemic drugs prescribed in the hospital. When other statins, 
Pravastatin 40 mg, Atorvastatin 40 mg, Simvastatin 80 mg, Rosuvastatin 10 mg, and 
Pravastatin 20 mg; were included to a hospital formulary, the expenditure for statin 
drugs per patient were changed to +7%, +151%, −24%, +169, and −26%, respec-
tively; while the market share for each drug at the time of ﬁ rst prescribe was 1.9%, 
0.4%, 0.2%, 2.8%, and 1.0% respectively. It was found that when a new statin with 
the same generic name but different strength was prescribed, the average statin expen-
diture was reduced; while new generic statins increased the expenditure. The average 
cost of statins per patient after including Pravastatin 20 mg to the formulary in 2006 
was US$45.02; which was 544% of the baseline statins cost in 2003. CONCLU-
SIONS: The hospital administrator should employ effective strategies to control uti-
lization of high price drugs; also prevent excessive drug promotion. 
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OBJECTIVES: To the estimate the health-care utilization patterns and costs related 
to ST-elevation acute myocardial infarction(STEMI) and understand the pattern of 
anti-thrombolytic use after stenting with a Korean population based design. 
METHODS: We extracted the insurance claims records of STEMI patients deﬁ ned as 
diagnosed with AMI and admitted by emergency room from Korea National Health 
Insurance claims database. We examined the health-care service provided to stent naïve 
patients among STEMI patients deﬁ ned as having no coronary-stents during one-year 
washout-period and having stents during two-year intake-period (January 1, 2006–
December 31, 2007). Annual claims records were aggregated for each patient to produce 
patient-speciﬁ c information on total utilization, costs and anti-thrombolytic use. We 
examined the pattern of anti-thrombolytic use according to types of the ﬁ rst stents(group 
I as using drug-eluting stents [DES], group II as using bare-metal stents [BMS]) and types 
of revascularization method (group A-DES, group B-BMS, group C-balloon, group 
D-CABG). RESULTS: There were 19,120 subjects identiﬁ ed as STEMI patients. Each 
STEMI patient had 8.7 outpatient visits, 1.1 admission per year. The total costs for 
treating STEMI in the nation was estimated as Korean-won (KRW)106,666million. 
The per-capita insurance-covered costs were KRW3,721,390. Those increased until 
the age of 74 years and reduced after the age of 75 years. The annual number of claims 
in tertiary hospital was slightly fewer than secondary hospitals (13,303 vs. 13,730), 
but insurance-covered costs/claim in tertiary hospital were higher than those in second-
ary hospitals by KRW1,493,051. The duration of using Cilostazol from the ﬁ rst 
stenting to revascularization in group I was 79.12 days, while GroupII was 73.44 
days. The use of Cilostazol was longer in group IA (95.8 days) or IC (89.18 days) 
than group IIA (62.15 days) or group IIC (61.33 days). CONCLUSIONS: In Korea, 
the burden of illness for AMI is a signiﬁ cant issue. Cilostazol was used longer when 
DES were used at ﬁ rst stenting compared to BMS. Whether the longer usage of Cilo-
stazol results in better outcome needs further research. 
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OBJECTIVES: Pharmacist-managed anticoagulation clinics (ACC) have been proven 
to provide positive outcomes in both overseas and local tertiary settings as part of a 
health-care team in caring for patients on warfarin therapy. However, currently, there 
is no published study on the effectiveness of pharmacist-managed ACC in the primary 
care settings in Singapore. Therefore, the primary objectives of this study were to 
determine the effectiveness of pharmacist-managed ACC in maintaining INR within 
the therapeutic range, and their associations with patient demographics. The second-
ary objective was to examine the incidence of warfarin-related adverse effects. 
METHODS: This was a retrospective, time-series study conducted in nine outpatient 
primary care clinics in Singapore from September to December 2009. All patients aged 
≥21 years with at least three visits with the ACC pharmacists within the ﬁ rst 12 months 
of physician referral were included in this study. Patient demographics and clinical 
outcomes, such as INR and incidence of warfarin-related adverse events, were col-
lected at ﬁ rst visit to ACC and at every 4-month interval for a total of 12 months. 
RESULTS: A total of 269 patients were under the care of ACC pharmacists from April 
2008 to May 2009, and of which 82 (30%) met the inclusion criteria. INR was 
maintained at therapeutic range throughout the 12-month period with minimal ﬂ uc-
tuations between each visit (P = 0.621). There was no association between INR and 
patient demographics except for intake of vitamins, supplements and herbal medica-
tions (P = 0.006) and change in medications (P = 0.039) at the 12th month. Docu-
mented warfarin-related adverse events included gingival bleeds (1; 1%), leg cramps 
(5; 6%), and swells (5; 6%). CONCLUSIONS: Pharmacist-managed ACC in the 
primary care settings in Singapore were effective in maintaining INR within the thera-
peutic range. The service also minimized the frequency of adverse events commonly 
associated with warfarin therapy. 
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OBJECTIVES: Blood pressure (BP) values in response to antihypertensive treatment 
are inﬂ uenced by both physician- and patient-level factors. We quantiﬁ ed summary 
estimates of variability in BP values attributable to a physician-level class effect across 
six observational studies. METHODS: We evaluated 90-day BP data on 14,116 
patients, in whom prior treatment failed or was not tolerated, who received valsartan-
based therapy for the treatment of hypertension. Data were collected during six 
consecutive prospective, observational, multi-center, pharmaco-epidemiologic studies 
conducted in Belgium between 2005 and 2009. Each study was designed to collect 
data from patients and their treating physicians. We applied a two-level hierarchical 
linear modeling method, using mixed-effects regression with residual maximum likeli-
hood estimation. From these data, intraclass correlation coefﬁ cients (ICC)s were 
calculated to quantify the variability in 90-day systolic BP (SBP) and diastolic BP (DBP) 
values attributable to within-physician variability in each study. We then completed 
a random-effects meta-analysis of ICC point estimates and variance from each study, 
to account for within- and between-study differences, and derived ICC summary 
estimates and 95% conﬁ dence intervals (CI). RESULTS: Summary estimates of abso-
lute reduction in 90-day SBP and DBP across studies were −18.17 mmHg (95% CI = 
−16.84 to −19.51 mmHg) and −9.73 mmHg (95% CI = −9.22 to −10.24 mmHg) 
respectively. ICCs for SBP ranged from 0.210 to 0.277, with a random-effects 
summary estimate of 0.238 (95% CI = 0.220 to 0.256; P < 0.0001; = 0.002; I2 < 
1%). ICCs for DBP ranged from 0.176 to 0.282, with a random-effects summary 
estimate of 0.255 (95% CI = 0.229 to 0.282; P < 0.0001; = 0.022; I2 = 45.69%). 
CONCLUSIONS: Considering within- and between-study differences in ICC, the 
average proportion of variance in 90-day SBP and DBP values attributable to a phy-
sician-level class effect was between 22.0% and 25.6%, and 22.9% and 28.2%, 
respectively. Further research is warranted to identify speciﬁ c and amenable physician-
level factors that contribute to higher BP values in response to antihypertensive 
treatment. 
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OBJECTIVES: To explore general public’s awareness and perceptions toward the role 
of community pharmacists in the provision of health related education and counsel-
